PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Journal of Gynecologic Oncology · 2026 · 37 (4)
DOI: 10.3802/jgo.2026.37.e75 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Wei-Ting Chao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Neoplasm Recurrence, Local, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital Yunlin Branch, Taipei Veterans General Hospital, Taiwan National Science and Technology Council, Executive Yuan.
Abstract (Originalsprache)
OBJECTIVE: This study aimed to assess prognosis related to poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy (MT) in newly diagnosed patients with advanced-stage epithelial ovarian cancer (adsOC, primary setting). Additionally, it evaluated the effect on recurrent patients after the front- or second-line PARPi MT (recurrence setting). METHODS: This multicenter retrospective study analyzed adsOC patients undergoing standard of care therapy (cytoreductive surgery and chemotherapy), regardless whether PARPi MT was followed or not from December 2011 to May 2023. The prognostic factors affecting survival outcomes (progression-free survival [PFS] and overall survival [OS]) in primary and recurrence settings were analyzed. RESULTS: A total of 218 patients were analyzed, including 25% with BRCAm, 13% with homologous recombination deficiency (HRD), and 62% with homologous recombination proficiency (HRP). The median follow-up was 35.5 months. In primary setting, International Federation of Gynecology and Obstetrics IIIC/IV, Eastern Cooperative Oncology Group (ECOG) >1, neoadjuvant chemotherapy, non-high-grade serous carcinoma (HGSOC) or non-endometrioid, HRP and absence of PARPi MT were associated with worse outcome. In recurrence setting, ECOG >1, platinum-resistance, non-HGSOC or non-endometrioid, non-BRCAm and previous PARPi MT were associated with poor prognosis. Rechallenge of PARPi in recurrent patients did not show statistically different outcome compared to those without PARPi. CONCLUSION: Besides, the best survival occurring in adsOC patients with BRCAm, HRD patients treated with PARPi MT also experienced significantly prolonged PFS and OS. However, prior frontline PARPi MT was associated with poorer OS if the recurrence occurred. Treatment for recurrence status with PARPi MT did not show survival benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Obstetrics and Gynecology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Department of Obstetrics and Gynecology, National Taiwan University Hospital, Yunlin Branch, Douliu, Taiwan.
ORCID-Profile: Wei-Ting Chao, Yu-Wen Sung, Kuan-Ju Huang, Lian-Shung Yeh, Bor-Ching Sheu, Wen-Chun Chang, Shang-Hsuan Peng, Po-Han Lin, Peng-Hui Wang
Förderung
- National Taiwan University Hospital Yunlin Branch
- Taipei Veterans General Hospital
- Taiwan National Science and Technology Council, Executive Yuan
- Taiwan Female Cancer Foundation
Zitieren
APA
Chao, W. T., Sung, Y. W., Huang, K. J., Yeh, L. S., Sheu, B. C., Chang, W. C., Peng, S. H., Lin, P. H., & Wang, P. H. (2026). PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan. Journal of Gynecologic Oncology, 37(4). https://doi.org/10.3802/jgo.2026.37.e75
Vancouver
Chao WT, Sung YW, Huang KJ, Yeh LS, Sheu BC, Chang WC, et al. PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan. Journal of Gynecologic Oncology. 2026;37(4). doi:10.3802/jgo.2026.37.e75
BibTeX
@article{Chao2026,
author = {Chao, Wei-Ting and Sung, Yu-Wen and Huang, Kuan-Ju and Yeh, Lian-Shung and Sheu, Bor-Ching and Chang, Wen-Chun and Peng, Shang-Hsuan and Lin, Po-Han and Wang, Peng-Hui},
title = {PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan},
journal = {Journal of Gynecologic Oncology},
year = {2026},
volume = {37},
number = {4},
doi = {10.3802/jgo.2026.37.e75}
}
EUVIMED